Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 17/20 | 0.82 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5576649 | 1.00 | CCR5 (0.82) | CCR5NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL5572584 | 0.95 | CCR5 (0.77) | CCR5CHRM2CHRM3 | |
| SCHEMBL5575950 | 0.95 | CCR5 (0.77) | CCR5CHRM2CHRM3 | |
| SCHEMBL5575948 | 0.95 | CCR5 (0.77) | CCR5CHRM2CHRM3 | |
| SCHEMBL5572581 | 0.95 | CCR5 (0.77) | CCR5CHRM2CHRM3 | |
| SCHEMBL5576118 | 0.94 | CCR5 (0.76) | CCR5NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL5573657 | 0.94 | CCR5 (0.76) | CCR5CHRM2CHRM3 | |
| SCHEMBL5576113 | 0.94 | CCR5 (0.76) | CCR5NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL5573651 | 0.94 | CCR5 (0.76) | CCR5CHRM2CHRM3 | |
| SCHEMBL5573661 | 0.94 | CCR5 (0.76) | CCR5CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | CCR5 1/4885NPC1 473/4885RAB9A 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.